Josh Gottheimer
Josh Gottheimer (D-NJ) sold $1M-$5M of $MSFT (Microsoft Corporation - Common Stock (MSFT) [OP]) on Nov 19, 2024, part of 37 transactions in this filing (21 buys, 16 sells).
HillSignal flagged 4 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Companies in this filing · 20
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
Sign Up to See More
See the full trade breakdown, suspicious timing flags, and how this filing connects to active legislation.
Get Free Access →Suspicious Timing Detected
4 flagsRep. Gottheimer bought $1K-$15K in $JNJ on Nov 22 and Nov 26, 2024 — 72-76 days before HR1062 (Growing and Preserving Innovation in America Act) was introduced, a bill that permanently locks in higher tax deductions for US multinationals like JNJ.
Rep. Gottheimer sold $1M-$5M in $MSFT options on Nov 19, 2024 — 78 days before S409 (No Tax Breaks for Outsourcing Act) was introduced, a bill that would eliminate tax deferral on foreign profits and increase effective tax rates for multinationals like Microsoft.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $MSFT | Microsoft Corporation - Common Stock (MSFT) [OP](Stock Option) | $1M-$5M | $417.79 | $414.44 | -0.8% | Nov 19, 2024 |
| BUY | $MSFT | Microsoft Corporation - Common Stock (MSFT) [OP](Stock Option) | $1M-$5M | $417.79 | $414.44 | -0.8% | Nov 19, 2024 |
| BUY | $MSFT | Microsoft Corporation - Common Stock (MSFT) [OP](Stock Option) | $1M-$5M | $417.79 | $414.44 | -0.8% | Nov 19, 2024 |
| BUY | $APP | Applovin Corporation - Class A Common Stock (APP) [ST] | $1K-$15K | $286.43 | — | — | Nov 11, 2024 |
| BUY | $DHI | D.R. Horton, Inc. Common Stock (DHI) [ST] | $1K-$15K | $167.64 | — | — | Nov 1, 2024 |
| BUY | $D | Dominion Energy, Inc. Common Stock (D) [ST] | $1K-$15K | $59.12 | — | — | Nov 26, 2024 |
| BUY | $JNJ | Johnson & Johnson Common Stock (JNJ) [ST] | $1K-$15K | $155.17 | $227.21 | +46.4% | Nov 22, 2024 |
| BUY | $JNJ | Johnson & Johnson Common Stock (JNJ) [ST] | $1K-$15K | $155.17 | $227.21 | +46.4% | Nov 26, 2024 |
| BUY | $KKR | KKR & Co. Inc. Common Stock (KKR) [ST] | $1K-$15K | $152.78 | — | — | Nov 19, 2024 |
| BUY | $MELI | MercadoLibre, Inc. - Common Stock (MELI) [ST] | $1K-$15K | — | — | — | Nov 15, 2024 |
Connected Legislative Activity
5 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Unplug the Electric Vehicle Charging Stations Program Act
H.R. 1513 targets $7.5 billion in federal EV charging grants for repeal. The bill is in early committee stage but has a companion Senate bill, increasing its probability of advancement. Pure-play charging companies EVgo, ChargePoint, and Blink face direct revenue risk from the loss of NEVI and CFI capital co-funding. Tesla faces indirect headwinds from slower EV adoption, though its proprietary Supercharger network and vehicle sales buffer the impact.
No Tax Breaks for Outsourcing Act
The No Tax Breaks for Outsourcing Act (S409) would eliminate tax deferral on foreign profits for U.S. multinationals, increasing effective tax rates by 5-8 percentage points. The bill is in early stages (referred to Senate Finance Committee, 19 cosponsors) and poses a 4-8% annual net income headwind for high international-exposure companies. Despite 8-30% rallies in the last 30 days across MSFT, AAPL, GOOGL, KO, PG, XOM, and CVX, this legislative risk is not currently priced into valuations.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
Growing and Preserving Innovation in America Act of 2025
HR1062 permanently locks in higher FDII and GILTI deductions for US multinationals, preventing a ~3.3 ppt effective tax rate increase on foreign IP income scheduled for 2026. This directly boosts after-tax net income for companies with large international revenue streams, including MSFT, AAPL, GOOGL, AMZN, NVDA, JNJ, PFE, KO, and PG. The bill is in early committee stage — structural impact is contingent on passage through the 119th Congress.
Repeal Community Development Block Grants Act of 2025
HR1133 is an early-stage bill to eliminate the Community Development Block Grant program. Passage probability is very low given single sponsorship and no committee action since referral. Bearish for homebuilders reliant on subsidized infrastructure, but near-term market impact is negligible.
Other Filings by Josh Gottheimer
Free — no credit card
Get the next Gottheimer trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.